Open AccessLong-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity
Author(s) -
Christine H. ten Hove,
Roseanne J.S. Vliegenthart,
Arjan B. te Pas,
Emma Brouwer,
Monique Rijken,
Aleid G. van WassenaerLeemhuis,
Anton H. van Kaam,
Wes Onland
Publication year - 2016
Publication title -
neonatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.399
H-Index - 84
eISSN - 1661-7819
pISSN - 1661-7800
DOI - 10.1159/000444006
Subject(s) - medicine , apnea of prematurity , doxapram , gestational age , bronchopulmonary dysplasia , pediatrics , cerebral palsy , birth weight , apnea , retrospective cohort study , anesthesia , pregnancy , surgery , physical therapy , genetics , biology
Doxapram has been advocated as a treatment for persistent apnea of prematurity (AOP).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom